Clinical Trial Update: The Impact of the Routine Aminophylline Administration Following Regadenoson Stress on SPECT Myocardial Perfusion [Phase 4]

View source ↗

Summary

A Phase 4 trial investigating the impact of routine aminophylline after regadenoson stress on SPECT myocardial perfusion was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• Aminophylline (aminophylline)
• Regadenoson (Regadenoson)
• SPECT myocardial perfusion

Snippet

Sponsor: Rush University Medical Center | Conditions: Coronary Artery Disease | Phase 4 | Status: WITHDRAWN